|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- February 12, 2002
CopyrightCOPYRIGHT 2002 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
3M Drug Delivery Systems Division, of St. Paul, Minn., reported results of its initial evaluation of hydrofluoroalkane (HFA)-based metered dose inhalation (MDI) systems for delivery of biotech molecules. Using particle-engineering technology in the production of respirable particles, along with MDI formulation expertise, 3M demonstrated that selected therapeutic protein molecules retained their activity for periods of up to six months in the HFA MDIs.
Aphton Corp., of Miami, reported interim results of the gastric cancer Phase II trial with its immunogen, G17DT, at the 12th International Congress on Anti-Cancer Treatment in Paris. No side effects were reported ...